{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:02:30Z","timestamp":1794654150592,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-111072 and MOP-130373"],"award-info":[{"award-number":["MOP-111072 and MOP-130373"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["USAMRAA W81XWH-21-1-0426"],"award-info":[{"award-number":["USAMRAA W81XWH-21-1-0426"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","award":["21438"],"award-info":[{"award-number":["21438"]}],"id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["417929"],"award-info":[{"award-number":["417929"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myotonic dystrophy, or dystrophia myotonica type 1 (DM1), is a multi-systemic disorder and is the most common adult form of muscular dystrophy. It affects not only muscles but also many organs, including the brain. Cerebral impairments include cognitive deficits, daytime sleepiness, and loss of visuospatial and memory functions. The expression of mutated transcripts with CUG repeats results in a gain of toxic mRNA function. The antisense oligonucleotide (ASO) strategy to treat DM1 brain deficits is limited by the fact that ASOs do not cross the blood\u2013brain barrier after systemic administration, indicating that other methods of delivery should be considered. ASO technology has emerged as a powerful tool for developing potential new therapies for a wide variety of human diseases, and its potential has been proven in a recent clinical trial. Targeting <jats:italic>DMPK<\/jats:italic> mRNA in neural cells derived from human induced pluripotent stem cells obtained from a DM1 patient with the IONIS 486178 ASO abolished CUG-expanded foci, enabled nuclear redistribution of MBNL1\/2, and corrected aberrant splicing. Intracerebroventricular injection of the IONIS 486178 ASO in DMSXL mice decreased the levels of mutant <jats:italic>DMPK<\/jats:italic> mRNAs by up to 70% throughout different brain regions. It also reversed behavioral abnormalities following neonatal administration. The present study indicated that the IONIS 486178 ASO targets mutant <jats:italic>DMPK<\/jats:italic> mRNAs in the brain and strongly supports the feasibility of a therapy for DM1 patients based on the intrathecal injection of an ASO.<\/jats:p>","DOI":"10.1038\/s41434-022-00316-7","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T02:02:33Z","timestamp":1643076153000},"page":"698-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1"],"prefix":"10.1038","volume":"29","author":[{"given":"Siham","family":"Ait Benichou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Jauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi\u00e9ry","family":"De Serres-B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-6684","authenticated-orcid":false,"given":"Karen K.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Frank","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9500-2839","authenticated-orcid":false,"given":"Mohamed","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Puymirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"316_CR1","volume-title":"Myotonic Dystrophy","author":"H PS","year":"2001","unstructured":"PS H. Myotonic Dystrophy. London: WB Saunders; 2001."},{"key":"316_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000369343","volume":"43","author":"A Theadom","year":"2014","unstructured":"Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43:259\u201368.","journal-title":"Neuroepidemiology"},{"key":"316_CR3","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1212\/01.WNL.0000144343.91136.CF","volume":"63","author":"G Bassez","year":"2004","unstructured":"Bassez G, Lazarus A, Desguerre I, Varin J, Laforet P, Becane HM, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology. 2004;63:1939\u201341.","journal-title":"Neurology"},{"key":"316_CR4","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1056\/NEJMoa062800","volume":"358","author":"WJ Groh","year":"2008","unstructured":"Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688\u201397.","journal-title":"N Engl J Med"},{"key":"316_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/adc.68.2.177","volume":"68","author":"W Reardon","year":"1993","unstructured":"Reardon W, Newcombe R, Fenton I, Sibert J, Harper PS. The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child. 1993;68:177\u201381.","journal-title":"Arch Dis Child"},{"key":"316_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1542\/peds.113.4.811","volume":"113","author":"C Campbell","year":"2004","unstructured":"Campbell C, Sherlock R, Jacob P, Blayney M. Congenital myotonic dystrophy: assisted ventilation duration and outcome. Pediatrics. 2004;113:811\u20136.","journal-title":"Pediatrics"},{"key":"316_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0022-510X(93)90072-7","volume":"115","author":"AT Hageman","year":"1993","unstructured":"Hageman AT, Gabre\u00ebls FJ, Liem KD, Renkawek K, Boon JM. Congenital myotonic dystrophy; a report on thirteen cases and a review of the literature. J Neurol Sci. 1993;115:95\u2013101.","journal-title":"J Neurol Sci"},{"key":"316_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5409\/wjcp.v4.i4.66","volume":"4","author":"G Ho","year":"2015","unstructured":"Ho G, Cardamone M, Farrar M. Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions. World journal of clinical pediatrics. 2015;4:66\u201380.","journal-title":"World journal of clinical pediatrics"},{"key":"316_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1212\/WNL.0000000000002845","volume":"87","author":"NE Johnson","year":"2016","unstructured":"Johnson NE, Butterfield R, Berggren K, Hung M, Chen W, DiBella D, et al. Disease burden and functional outcomes in congenital myotonic dystrophy: a cross-sectional study. Neurology. 2016;87:160\u20137.","journal-title":"Neurology"},{"key":"316_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/16501970500477967","volume":"38","author":"G Antonini","year":"2006","unstructured":"Antonini G, Soscia F, Giubilei F, De Carolis A, Gragnani F, Morino S, et al. Health-related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. J Rehabil Med. 2006;38:181\u20135.","journal-title":"J Rehabil Med"},{"key":"316_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0883073813484804","volume":"29","author":"NE Johnson","year":"2014","unstructured":"Johnson NE, Luebbe E, Eastwood E, Chin N, Moxley RT, Heatwole CR. The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms. J Child Neurol. 2014;29:983\u20136.","journal-title":"J Child Neurol"},{"key":"316_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/0887-8994(91)90102-Q","volume":"7","author":"A Garcia-Alix","year":"1991","unstructured":"Garcia-Alix A, Caba\u00f1as F, Morales C, Pellicer A, Echevarria J, Paisan L, et al. Cerebral abnormalities in congenital myotonic dystrophy. Pediatr Neurol. 1991;7:28\u201332.","journal-title":"Pediatr Neurol"},{"key":"316_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s004010000216","volume":"100","author":"A Endo","year":"2000","unstructured":"Endo A, Motonaga K, Arahata K, Harada K, Yamada T, Takashima S. Developmental expression of myotonic dystrophy protein kinase in brain and its relevance to clinical phenotype. Acta Neuropathol. 2000;100:513\u201320.","journal-title":"Acta Neuropathol"},{"key":"316_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fnmol.2013.00057","volume":"6","author":"ML Caillet-Boudin","year":"2014","unstructured":"Caillet-Boudin ML, Fernandez-Gomez FJ, Tran H, Dhaenens CM, Buee L, Sergeant N. Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci. 2014;6:57.","journal-title":"Front Mol Neurosci"},{"key":"316_CR15","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/hmg\/10.19.2143","volume":"10","author":"N Sergeant","year":"2001","unstructured":"Sergeant N, Sablonni\u00e8re B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet. 2001;10:2143\u201355.","journal-title":"Hum Mol Genet"},{"key":"316_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1651-2227.1992.tb12312.x","volume":"81","author":"Y Tanabe","year":"1992","unstructured":"Tanabe Y, Iai M, Tamai K, Fujimoto N, Sugita K. Neuroradiological findings in children with congenital myotonic dystrophy. Acta Paediatr. 1992;81:613\u20137.","journal-title":"Acta Paediatr"},{"key":"316_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0960-8966(01)00324-8","volume":"12","author":"A Di Costanzo","year":"2002","unstructured":"Di Costanzo A, Di Salle F, Santoro L, Bonavita V, Tedeschi G. Brain MRI features of congenital- and adult-form myotonic dystrophy type 1: case-control study. Neuromuscul Disord. 2002;12:476\u201383.","journal-title":"Neuromuscul Disord"},{"key":"316_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00381-015-2993-y","volume":"32","author":"IS Mutchnick","year":"2016","unstructured":"Mutchnick IS, Thatikunta MA, Gump WC, Stewart DL, Moriarty TM. Congenital myotonic dystrophy: ventriculomegaly and shunt considerations for the pediatric neurosurgeon. Childs Nerv Syst. 2016;32:609\u201316.","journal-title":"Childs Nerv Syst"},{"key":"316_CR19","doi-asserted-by":"publisher","first-page":"105532","DOI":"10.1016\/j.nbd.2021.105532","volume":"160","author":"T De Serres-B\u00e9rard","year":"2021","unstructured":"De Serres-B\u00e9rard T, Pierre M, Chahine M, Puymirat J. Deciphering the mechanisms underlying brain alterations and cognitive impairment in congenital myotonic dystrophy. Neurobiol Dis. 2021;160:105532.","journal-title":"Neurobiol Dis"},{"key":"316_CR20","first-page":"385","volume":"69","author":"JD Brook","year":"1992","unstructured":"Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell. 1992;69:385.","journal-title":"Cell"},{"key":"316_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1126\/science.1546326","volume":"255","author":"YH Fu","year":"1992","unstructured":"Fu YH, Pizzuti A, Fenwick RG, King J, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992;255:1256\u20138.","journal-title":"Science"},{"key":"316_CR22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1546325","volume":"255","author":"M Mahadevan","year":"1992","unstructured":"Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3\u2019 untranslated region of the gene. Science. 1992;255:1253\u20135.","journal-title":"Science"},{"key":"316_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/355545a0","volume":"355","author":"HG Harley","year":"1992","unstructured":"Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature. 1992;355:545\u20136.","journal-title":"Nature"},{"key":"316_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1083\/jcb.128.6.995","volume":"128","author":"KL Taneja","year":"1995","unstructured":"Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol. 1995;128:995\u20131002.","journal-title":"J Cell Biol"},{"key":"316_CR25","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","volume":"19","author":"JW Miller","year":"2000","unstructured":"Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439\u201348.","journal-title":"EMBO J"},{"key":"316_CR26","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1074\/jbc.M005960200","volume":"276","author":"NA Timchenko","year":"2001","unstructured":"Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem. 2001;276:7820\u20136.","journal-title":"J Biol Chem"},{"key":"316_CR27","doi-asserted-by":"publisher","first-page":"20333","DOI":"10.1073\/pnas.0809045105","volume":"105","author":"A Kalsotra","year":"2008","unstructured":"Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci USA. 2008;105:20333\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"316_CR28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1161\/01.RES.0000193598.89753.e3","volume":"97","author":"A Mankodi","year":"2005","unstructured":"Mankodi A, Lin X, Blaxall BC, Swanson MS, Thornton CA. Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res. 2005;97:1152\u20135.","journal-title":"Circ Res"},{"key":"316_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.neuro.29.051605.113014","volume":"29","author":"LP Ranum","year":"2006","unstructured":"Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci. 2006;29:259\u201377.","journal-title":"Annu Rev Neurosci"},{"key":"316_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molcel.2014.08.027","volume":"56","author":"R Batra","year":"2014","unstructured":"Batra R, Charizanis K, Manchanda M, Mohan A, Li M, Finn DJ, et al. Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol Cell. 2014;56:311\u201322.","journal-title":"Mol Cell"},{"key":"316_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.celrep.2015.07.029","volume":"12","author":"M Goodwin","year":"2015","unstructured":"Goodwin M, Mohan A, Batra R, Lee KY, Charizanis K, Fernandez Gomez FJ, et al. MBNL sequestration by toxic RNAs and RNA misprocessing in the myotonic dystrophy brain. Cell Rep. 2015;12:1159\u201368.","journal-title":"Cell Rep"},{"key":"316_CR32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/brain\/aws367","volume":"136","author":"O Hern\u00e1ndez-Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez-Hern\u00e1ndez O, Guiraud-Dogan C, Sicot G, Huguet A, Luilier S, Steidl E, et al. Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Brain. 2013;136:957\u201370.","journal-title":"Brain"},{"key":"316_CR33","doi-asserted-by":"publisher","first-page":"e25553","DOI":"10.4161\/rdis.25553","volume":"1","author":"O Hern\u00e1ndez-Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez-Hern\u00e1ndez O, Sicot G, Dinca DM, Huguet A, Nicole A, Bu\u00e9e L, et al. Synaptic protein dysregulation in myotonic dystrophy type 1: disease neuropathogenesis beyond missplicing. Rare Dis. 2013;1:e25553.","journal-title":"Rare Dis"},{"key":"316_CR34","doi-asserted-by":"publisher","first-page":"R116","DOI":"10.1093\/hmg\/ddr343","volume":"20","author":"G Sicot","year":"2011","unstructured":"Sicot G, Gourdon G, Gomes-Pereira M. Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges. Hum Mol Genet. 2011;20:R116\u201323.","journal-title":"Hum Mol Genet"},{"key":"316_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.cell.2012.06.041","volume":"150","author":"ET Wang","year":"2012","unstructured":"Wang ET, Cody NA, Jog S, Biancolella M, Wang TT, Treacy DJ, et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell. 2012;150:710\u201324.","journal-title":"Cell"},{"key":"316_CR36","doi-asserted-by":"publisher","first-page":"108634","DOI":"10.1016\/j.celrep.2020.108634","volume":"34","author":"BA Otero","year":"2021","unstructured":"Otero BA, Poukalov K, Hildebrandt RP, Thornton CA, Jinnai K, Fujimura H, et al. Transcriptome alterations in myotonic dystrophy frontal cortex. Cell Rep. 2021;34:108634.","journal-title":"Cell Rep"},{"key":"316_CR37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/hmg\/9.8.1185","volume":"9","author":"H Seznec","year":"2000","unstructured":"Seznec H, Lia-Baldini AS, Duros C, Fouquet C, Lacroix C, Hofmann-Radvanyi H, et al. Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum Mol Genet. 2000;9:1185\u201394.","journal-title":"Hum Mol Genet"},{"key":"316_CR38","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1371\/journal.pgen.0030052","volume":"3","author":"M Gomes-Pereira","year":"2007","unstructured":"Gomes-Pereira M, Foiry L, Nicole A, Huguet A, Junien C, Munnich A, et al. CTG trinucleotide repeat \u201cbig jumps\u201d: large expansions, small mice. PLoS Genet. 2007;3:e52.","journal-title":"PLoS Genet"},{"key":"316_CR39","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.bbadis.2013.03.002","volume":"1832","author":"G Sicot","year":"2013","unstructured":"Sicot G, Gomes-Pereira M. RNA toxicity in human disease and animal models: from the uncovering of a new mechanism to the development of promising therapies. Biochim Biophys Acta. 2013;1832:1390\u2013409.","journal-title":"Biochim Biophys Acta"},{"key":"316_CR40","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","volume":"289","author":"A Mankodi","year":"2000","unstructured":"Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000;289:1769\u201373.","journal-title":"Science"},{"key":"316_CR41","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1073\/pnas.0708519105","volume":"105","author":"JP Orengo","year":"2008","unstructured":"Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA. Expanded CTG repeats within the DMPK 3\u2019 UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci USA. 2008;105:2646\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"316_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41422-019-0264-2","volume":"30","author":"Q Yin","year":"2020","unstructured":"Yin Q, Wang H, Li N, Ding Y, Xie Z, Jin L, et al. Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1. Cell Res. 2020;30:133\u201345.","journal-title":"Cell Res"},{"key":"316_CR43","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1101\/gad.328963.119","volume":"33","author":"CA Nutter","year":"2019","unstructured":"Nutter CA, Bubenik JL, Oliveira R, Ivankovic F, Sznajder \u0141, Kidd BM, et al. Cell-type-specific dysregulation of RNA alternative splicing in short tandem repeat mouse knockin models of myotonic dystrophy. Genes Dev. 2019;33:1635\u201340.","journal-title":"Genes Dev"},{"key":"316_CR44","doi-asserted-by":"publisher","first-page":"e72907","DOI":"10.1371\/journal.pone.0072907","volume":"8","author":"JT Gladman","year":"2013","unstructured":"Gladman JT, Mandal M, Srinivasan V, Mahadevan MS. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1). PLoS One. 2013;8:e72907.","journal-title":"PLoS One"},{"key":"316_CR45","first-page":"1297","volume":"7","author":"I Garc\u00eda-Alcover","year":"2014","unstructured":"Garc\u00eda-Alcover I, Colonques-Bellmunt J, Garijo R, Tormo JR, Artero R, \u00c1lvarez-Abril MC, et al. Development of a Drosophila melanogaster spliceosensor system for in vivo high-throughput screening in myotonic dystrophy type 1. Dis Model Mech. 2014;7:1297\u2013306.","journal-title":"Dis Model Mech"},{"key":"316_CR46","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1093\/hmg\/ddl137","volume":"15","author":"M de Haro","year":"2006","unstructured":"de Haro M, Al-Ramahi I, De Gouyon B, Ukani L, Rosa A, Faustino NA, et al. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet. 2006;15:2138\u201345.","journal-title":"Hum Mol Genet"},{"key":"316_CR47","doi-asserted-by":"publisher","first-page":"e1595","DOI":"10.1371\/journal.pone.0001595","volume":"3","author":"A Garcia-Lopez","year":"2008","unstructured":"Garcia-Lopez A, Monferrer L, Garcia-Alcover I, Vicente-Crespo M, Alvarez-Abril MC, Artero RD. Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS One. 2008;3:e1595.","journal-title":"PLoS One"},{"key":"316_CR48","first-page":"143","volume":"7","author":"PK Todd","year":"2014","unstructured":"Todd PK, Ackall FY, Hur J, Sharma K, Paulson HL, Dowling JJ. Transcriptional changes and developmental abnormalities in a zebrafish model of myotonic dystrophy type 1. Dis Model Mech. 2014;7:143\u201355.","journal-title":"Dis Model Mech"},{"key":"316_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1242\/dmm.004150","volume":"4","author":"LE Machuca-Tzili","year":"2011","unstructured":"Machuca-Tzili LE, Buxton S, Thorpe A, Timson CM, Wigmore P, Luther PK, et al. Zebrafish deficient for Muscleblind-like 2 exhibit features of myotonic dystrophy. Dis Model Mech. 2011;4:381\u201392.","journal-title":"Dis Model Mech"},{"key":"316_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.scr.2017.12.010","volume":"26","author":"L Martineau","year":"2018","unstructured":"Martineau L, Racine V, Benichou SA, Puymirat J. Lymphoblastoids cell lines - Derived iPSC line from a 26-year-old myotonic dystrophy type 1 patient carrying (CTG). Stem Cell Res. 2018;26:103\u20136.","journal-title":"Stem Cell Res"},{"key":"316_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/cell.2012.0086","volume":"15","author":"G Xia","year":"2013","unstructured":"Xia G, Santostefano KE, Goodwin M, Liu J, Subramony SH, Swanson MS, et al. Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis. Cellular Reprogram. 2013;15:166\u201377.","journal-title":"Cellular Reprogram"},{"key":"316_CR52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbrc.2019.05.176","volume":"516","author":"H Poulin","year":"2019","unstructured":"Poulin H, Martineau L, Racine V, Puymirat J, Chahine M. Differentiation of lymphoblastoid-derived iPSCs into functional cardiomyocytes, neurons and myoblasts. Biochem Biophys Res Commun. 2019;516:222\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"316_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82007-8","volume":"11","author":"H Poulin","year":"2021","unstructured":"Poulin H, Mercier A, Djemai M, Pouliot V, Deschenes I, Boutjdir M, et al. iPSC-derived cardiomyocytes from patients with myotonic dystrophy type 1 have abnormal ion channel functions and slower conduction velocities. Sci Rep. 2021;11:2500.","journal-title":"Sci Rep"},{"key":"316_CR54","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.nmd.2014.11.018","volume":"25","author":"V Algalarrondo","year":"2015","unstructured":"Algalarrondo V, Wahbi K, Sebag F, Gourdon G, Beldjord C, Azibi K, et al. Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1. Neuromuscul Disord. 2015;25:308\u201320.","journal-title":"Neuromuscul Disord"},{"key":"316_CR55","doi-asserted-by":"publisher","first-page":"e1003043","DOI":"10.1371\/journal.pgen.1003043","volume":"8","author":"A Huguet","year":"2012","unstructured":"Huguet A, Medja F, Nicole A, Vignaud A, Guiraud-Dogan C, Ferry A, et al. Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus. PLoS Genetics. 2012;8:e1003043.","journal-title":"PLoS Genetics"},{"key":"316_CR56","first-page":"622","volume":"6","author":"PA Panaite","year":"2013","unstructured":"Panaite PA, Kuntzer T, Gourdon G, Lobrinus JA, Barakat-Walter I. Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy. Dis Model Mech. 2013;6:622\u201331.","journal-title":"Dis Model Mech"},{"key":"316_CR57","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/1566523215666150630120537","volume":"15","author":"AF Klein","year":"2015","unstructured":"Klein AF, Dastidar S, Furling D, Chuah MK. Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy. Curr Gene Ther. 2015;15:329\u201337.","journal-title":"Curr Gene Ther"},{"key":"316_CR58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","volume":"488","author":"TM Wheeler","year":"2012","unstructured":"Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature. 2012;488:111\u20135.","journal-title":"Nature"},{"key":"316_CR59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","volume":"7","author":"D Jauvin","year":"2017","unstructured":"Jauvin D, Chretien J, Pandey SK, Martineau L, Revillod L, Bassez G, et al. Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice. Mol Therap Nucleic Acids. 2017;7:465\u201374.","journal-title":"Mol Therap Nucleic Acids"},{"key":"316_CR60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1124\/jpet.115.226969","volume":"355","author":"SK Pandey","year":"2015","unstructured":"Pandey SK, Wheeler TM, Justice SL, Kim A, Younis HS, Gattis D, et al. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Therap. 2015;355:329\u201340.","journal-title":"J Pharmacol Exp Therap"},{"key":"316_CR61","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/hmg\/ddaa060","volume":"29","author":"RS Yadava","year":"2020","unstructured":"Yadava RS, Yu Q, Mandal M, Rigo F, Bennett CF, Mahadevan MS. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3\u2019UTR RNA. Hum Mol Genet. 2020;29:1440\u201353.","journal-title":"Hum Mol Genet"},{"key":"316_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nbt0217-99","volume":"35","author":"E Dolgin","year":"2017","unstructured":"Dolgin E. Spinal muscular atrophy approval boosts antisense drugs. Nat Biotechnol. 2017;35:99\u2013100.","journal-title":"Nat Biotechnol"},{"key":"316_CR63","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1152\/jn.01350.2007","volume":"99","author":"A Chatelier","year":"2008","unstructured":"Chatelier A, Dahllund L, Eriksson A, Krupp J, Chahine M. Biophysical properties of human Na v1.7 splice variants and their regulation by protein kinase A. JNeurophysiol. 2008;99:2241\u201350.","journal-title":"JNeurophysiol"},{"key":"316_CR64","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1081\/NCN-120022050","volume":"22","author":"ZS Cheruvallath","year":"2003","unstructured":"Cheruvallath ZS, Kumar RK, Rentel C, Cole DL, Ravikumar VT. Solid phase synthesis of phosphorothioate oligonucleotides utilizing diethyldithiocarbonate disulfide (DDD) as an efficient sulfur transfer reagent. Nucleosides Nucleotides Nucleic Acids. 2003;22:461\u20138.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"316_CR65","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.113.212407","volume":"350","author":"F Rigo","year":"2014","unstructured":"Rigo F, Chun SJ, Norris DA, Hung G, Lee S, Matson J, et al. Pharmacology of a central nervous system delivered 2\u2019-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Therap. 2014;350:46\u201355.","journal-title":"J Pharmacol Exp Therap"},{"key":"316_CR66","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/nat.2013.0443","volume":"23","author":"G Hung","year":"2013","unstructured":"Hung G, Xiao X, Peralta R, Bhattacharjee G, Murray S, Norris D, et al. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 2013;23:369\u201378.","journal-title":"Nucleic Acid Ther"},{"key":"316_CR67","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00418-015-1315-5","volume":"143","author":"G Xia","year":"2015","unstructured":"Xia G, Ashizawa T. Dynamic changes of nuclear RNA foci in proliferating DM1 cells. Histochem Cell Biol. 2015;143:557\u201364.","journal-title":"Histochem Cell Biol"},{"key":"316_CR68","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","volume":"13","author":"H Jiang","year":"2004","unstructured":"Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet. 2004;13:3079\u201388.","journal-title":"Hum Mol Genet"},{"key":"316_CR69","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/stem.1970","volume":"33","author":"G Xia","year":"2015","unstructured":"Xia G, Gao Y, Jin S, Subramony SH, Terada N, Ranum LP, et al. Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells. Stem Cells. 2015;33:1829\u201338.","journal-title":"Stem Cells"},{"key":"316_CR70","first-page":"379","volume":"77","author":"M Butler","year":"1997","unstructured":"Butler M, Stecker K, Bennett CF. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Investig. 1997;77:379\u201388.","journal-title":"Lab Investig"},{"key":"316_CR71","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/intimm\/dxh316","volume":"17","author":"ZF Yang","year":"2005","unstructured":"Yang ZF, Ho DW, Lau CK, Lam CT, Lum CT, Poon RT, et al. Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. Int Immunol. 2005;17:1391\u20137.","journal-title":"Int Immunol"},{"key":"316_CR72","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/mt.2016.97","volume":"24","author":"Y Gao","year":"2016","unstructured":"Gao Y, Guo X, Santostefano K, Wang Y, Reid T, Zeng D, et al. Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy. Mol Therap. 2016;24:1378\u201387.","journal-title":"Mol Therap"},{"key":"316_CR73","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddw266","volume":"25","author":"ST Carrell","year":"2016","unstructured":"Carrell ST, Carrell EM, Auerbach D, Pandey SK, Bennett CF, Dirksen RT, et al. Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice. Hum Mol Genet. 2016;25:4328\u201338.","journal-title":"Hum Mol Genet"},{"key":"316_CR74","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","volume":"15","author":"X Lin","year":"2006","unstructured":"Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet. 2006;15:2087\u201397.","journal-title":"Hum Mol Genet"},{"key":"316_CR75","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1172\/JCI32308","volume":"117","author":"GS Wang","year":"2007","unstructured":"Wang GS, Kearney DL, De Biasi M, Taffet G, Cooper TA. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Investig. 2007;117:2802\u201311.","journal-title":"J Clin Investig"},{"key":"316_CR76","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1126\/science.1088583","volume":"302","author":"RN Kanadia","year":"2003","unstructured":"Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, et al. A muscleblind knockout model for myotonic dystrophy. Science. 2003;302:1978\u201380.","journal-title":"Science"},{"key":"316_CR77","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.neuron.2012.05.029","volume":"75","author":"K Charizanis","year":"2012","unstructured":"Charizanis K, Lee KY, Batra R, Goodwin M, Zhang C, Yuan Y, et al. Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron. 2012;75:437\u201350.","journal-title":"Neuron"},{"key":"316_CR78","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/emmm.201303275","volume":"5","author":"KY Lee","year":"2013","unstructured":"Lee KY, Li M, Manchanda M, Batra R, Charizanis K, Mohan A, et al. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol Med. 2013;5:1887\u2013900.","journal-title":"EMBO Mol Med"},{"key":"316_CR79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnana.2019.00075","volume":"13","author":"KY Lee","year":"2019","unstructured":"Lee KY, Chang HC, Seah C, Lee LJ. Deprivation of Muscleblind-Like Proteins Causes Deficits in Cortical Neuron Distribution and Morphological Changes in Dendritic Spines and Postsynaptic Densities. Front Neuroanat. 2019;13:75.","journal-title":"Front Neuroanat"},{"key":"316_CR80","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24:1634\u201344.","journal-title":"Genes Dev"},{"key":"316_CR81","first-page":"9519","volume":"44","author":"FF Depreux","year":"2016","unstructured":"Depreux FF, Wang L, Jiang H, Jodelka FM, Rosencrans RF, Rigo F, et al. Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse. Nucleic Acids Res. 2016;44:9519\u201329.","journal-title":"Nucleic Acids Res"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00316-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:05:27Z","timestamp":1671062727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00316-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["316"],"URL":"https:\/\/doi.org\/10.1038\/s41434-022-00316-7","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee at CRCHU de Qu\u00e9bec.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"KKL, CFB, and FR are employees of Ionis Pharmaceuticals. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}